When is the best time to take Osimertinib/Tagressa? Medication Guide and Recommendations

As a third-generation EGFR inhibitor, Osimertinib has been widely used in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). It is particularly suitable for patients who develop the EGFR T790M mutation after initial treatment, as well as those with other types of EGFR mutations. When taking osimertinib, understanding the optimal timing and related dosing guidelines is crucial to ensure its efficacy and reduce adverse reactions.

Osimertinib is recommended to be taken orally at the same time every day, which helps establish a regular drug intake habit and ensures that the blood concentration of the drug remains stable. Patients are usually advised to take osimertinib after a meal, because taking the drug on an empty stomach may cause certain gastrointestinal adverse reactions (such as nausea, vomiting, etc.), and taking the drug after a meal can reduce the occurrence of these side effects. Although osimertinib is well tolerated, taking it after meals can reduce gastrointestinal discomfort and improve drug absorption.

As for the dose, the generally recommended dose is 80 mg per day. Take it in a single dose. Do not take it orally at the same time as other drugs. If a dose is missed, the patient should take it as soon as possible on the day they remember, but if it is close to the next dose, the missed dose should be skipped and the dose should not be doubled to make up for the missed dose. Dosage adjustments may be necessary in patients with impaired hepatic and renal function, so it is important to undergo a complete physical examination before initiating treatment.

During the course of taking the drug, patients also need regular examinations, including imaging tests and blood tests, to evaluate the efficacy of the drug and the occurrence of side effects. Although the side effects of osimertinib are relatively few, there may still be some reactions that affect the patient's daily life, such as rash, diarrhea, oral ulcers, etc., especially skin reactions. Therefore, patients need to closely monitor any abnormal symptoms during the medication and report it to the doctor in time so that the treatment plan can be adjusted in a timely manner.

Reference materials:https://go.drugbank.com/drugs/DB09330